Cholangiocarcinoma Clinical Trials

189 recruitingLast updated: June 17, 2026

There are 189 actively recruiting cholangiocarcinoma clinical trials across 34 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Shanghai, Shanghai Municipality, China, Hangzhou, Zhejiang, China. Updated daily from ClinicalTrials.gov.


Cholangiocarcinoma Trials at a Glance

189 actively recruiting trials for cholangiocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 79 trials, with the heaviest enrollment activity in Houston, Shanghai, and Hangzhou. Lead sponsors running cholangiocarcinoma studies include M.D. Anderson Cancer Center, Fudan University, and National Cancer Institute (NCI).

Browse cholangiocarcinoma trials by phase

Treatments under study

About Cholangiocarcinoma Clinical Trials

Looking for clinical trials for Cholangiocarcinoma? There are currently 91 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cholangiocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cholangiocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 189 trials

Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

CholangiocarcinomaPancreas CancerColorectal Neoplasms+2 more
National Cancer Institute (NCI)1,800 enrolled1 locationNCT01915225
Recruiting
Phase 1Phase 2

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

CholangiocarcinomaBile Duct NeoplasmBiliary Tract Malignancy
National Cancer Institute (NCI)31 enrolled1 locationNCT04645160
Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 2

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Colorectal, CancerCholangiocarcinomaColorectal Neoplasms+10 more
National Cancer Institute (NCI)70 enrolled1 locationNCT05286814
Recruiting
Phase 1Phase 2

Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

Biliary Tract CancerCholangiocarcinomaExtrahepatic Cholangiocarcinoma+2 more
Beijing Biotech30 enrolled1 locationNCT07641036
Recruiting

Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study

Intrahepatic Cholangiocarcinoma (Icc)
Peking Union Medical College Hospital90 enrolled1 locationNCT07640048
Recruiting
Phase 2

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

CholangiocarcinomaIDH Mutation
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest40 enrolled12 locationsNCT07260175
Recruiting

Liver Cancer Registry Platform

CholangiocarcinomaHepatocellular Carcinoma (HCC)
iOMEDICO AG1,000 enrolled1 locationNCT04510740
Recruiting
Phase 4

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

CholangiocarcinomaSolid Tumor MalignanciesGlioma+1 more
Rigel Pharmaceuticals16 enrolled2 locationsNCT07486713
Recruiting
Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled30 locationsNCT07213791
Recruiting
Phase 1

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Refractory Malignant Solid Neoplasm+4 more
University of Southern California36 enrolled2 locationsNCT05791448
Recruiting
Phase 1

Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer

Gallbladder CancerBiliary Tract NeoplasmsCholangiocarcinoma, Intrahepatic+2 more
Shanghai Zhongshan Hospital18 enrolled1 locationNCT07614061
Recruiting
Phase 2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc.120 enrolled65 locationsNCT05727176
Recruiting
Phase 2Phase 3

Trop2-targeted immunoPET Imaging of Solid Tumors

Liver CancerOvarian CancerCervical Cancer+11 more
RenJi Hospital400 enrolled1 locationNCT06851663
Recruiting
Not Applicable

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

CholangiocarcinomaRare CancersCancer of Unknown Primary Site
TargetCancer Foundation400 enrolled1 locationNCT04504604
Recruiting
Not Applicable

Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma

Perihilar Cholangiocarcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)122 enrolled1 locationNCT05546372
Recruiting

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Perihilar Cholangiocarcinoma. A Prospective Multicenter Study.

Unresectable Cholangiocarcinoma
Hospital Vall d'Hebron34 enrolled1 locationNCT04378023
Recruiting
Phase 2

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Not Applicable

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Pancreatic CancerMelanomaLiver Malignant Tumors+1 more
M.D. Anderson Cancer Center60 enrolled1 locationNCT05053555
Recruiting
Phase 1

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC)Hepatocellular Carcinoma (HCC)Gastric Cancer (GC)+1 more
Shenzhen Xinhe Biomedical48 enrolled2 locationsNCT07594964